NTRK2 (Neurotrophic tyrosine kinase, receptor, type 2)

Pan-TRK IHC has a false-positive rate of ∼4%, particularly in squamous cell carcinomas, underscoring the need for confirmatory NGS to validate IHC findings and assess fusion functionality. Functional NTRK1/2/3 fusions remain exceedingly rare in NSCLC, with a detection rate of 0.03% across our combined cohorts.

This case provides critical clinical evidence of the "driver versus passenger" phenomenon in precision oncology. It demonstrates that the epigenetic dominance of the SS18::SSX fusion can override the therapeutic relevance of a concurrent NTRK fusion. Our findings serve as a cautionary note: actionable targets detected via next-generation sequencing must be interpreted within the tumor's canonical biological context, as lineage-defining translocations may render secondary kinase alterations therapeutically inert.

None of the cases had genomic variants in TERT or CDKN2A. We believe FGFR1 fusions constitute a distinct subtype of Spitz neoplasm and FGFR1 should be added to the list of Spitz-associated genomic fusions.

Diazepam failed to exert significant effects in poly(I:C)-treated mice...In addition, the administration of 7,8-dihydroxyflavone, a tropomyosin receptor kinase B receptor agonist, significantly increased the time spent in the light compartment in the light-dark box test and ameliorated poly(I:C)-induced anxiety-like behavior. These findings suggest that the anxiolytic-like effects of HET may be associated with the suppression of peripheral inflammatory cytokine responses and restoration of hippocampal BDNF signaling under conditions mimicking viral infection-induced inflammation.

Most "Invalid" results were attributable to RNA degradation and resolved with freshly cut sections. These findings support the Idylla GeneFusion Assay as a rapid and practical frontline tool for NTRK fusion detection, particularly in settings with limited tissue or need for expedited decision-making, with reflex next-generation sequencing recommended for "Equivocal" cases or when fusion partner identification is required.

A Ki-67 index ≥50% was significantly correlated with improved EFS in both cohorts (both p<0.05). These findings indicate baseline tumor proliferation, particularly MKI67/Ki-67, as predictors of pathological response in NSCLC patients receiving neoadjuvant chemoimmunotherapy, supporting its potential clinical utility for patient selection.

P1/2, N=67, Recruiting, D3 Bio (Wuxi) Co., Ltd | Active, not recruiting --> Recruiting | Trial completion date: Apr 2028 --> Aug 2028 | Trial primary completion date: Apr 2028 --> Aug 2028

Our findings reveal unique features of TrkB, not present in the related neurotrophin receptors TrkA and TrkC, and suggest new directions to explore the role of sulfotyrosine in TrkB signalling and identify new TrkB-specific protein ligands. Investigation of the mechanism of action of TrkB agonist ZEB85 extends molecular understanding of TrkB activation.

Collectively, these data suggest that KET, particularly when administered repeatedly at low doses, could be a promising adjunctive therapy to enhance quality of life for cancer patients undergoing DOX chemotherapy. However, because key intermediate nodes were not directly measured and KET-only control groups were not included, the proposed mechanistic cascade should be regarded as a hypothetical integrative model that warrants further validation.

Our results support the incorporation of ALK immunohistochemistry as a screening tool and demonstrate the utility of anchored multiplex PCR-based RNA sequencing for the detection of therapeutically relevant fusions, particularly those with uncommon partners. This integrated approach may refine the diagnosis and support consideration of ALK-directed therapy in these rare tumors.

It also exhibited antiangiogenic effects and suppressed tumor growth in a xenograft model without overt toxicity. These findings support 31 as a promising multimechanistic lead for AML therapy, warranting further medicinal chemistry optimization to improve its pharmacokinetic properties and advance its development potential.

In CRC, TAT was 4.1, 5.3, and 10.2; QNS 0%, 0%, 7.5%; detection 63.9%, 62.5%, and 57.1%. OPA provides faster TAT and lower QNS rates with comparable detection of actionable alterations, supporting its use for community-based molecular testing in NSCLC and CRC.